Clinical Trial: A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07424287) titled 'A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC' on Feb. 13.

Brief Summary: This is a multicenter, randomized, open-label phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus investigator-selected chemotherapy in patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: NMIBC

Intervention: DRUG: SHR-1501 for Injection

SHR-1501 for injection.

DRUG: BCG for Injection

Bac...